MRKMerck Sharp & Dohme LLCFinished
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Hepatocellular Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 959 (final count)
- Started
- May 28, 2019
- Main results expected
- Mar 20, 2025
- Fully finished
- Sep 30, 2025
- Results posted
- Apr 24, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Recurrence-Free Survival (RFS)
Measured over: Up to approximately 69 months
Overall Survival (OS)
Measured over: Up to approximately 69 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03867084 · record last updated 2026-04-24 · checked 2026-11-09 15:47 UTC